2000/112/EC: Commission Decision of 14 January 2000 detailing the distribution between antigen banks of antigen reserves established within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines and amending Commission Decisions 93/590/EC and 97/348/EC (notified under document number C(2000) 1) (Text with EEA relevance)
Date: 2000-01-14
Institutions: European Commission
Subjects: France, Italy, United Kingdom, foot-and-mouth disease, research body, vaccine

8. 2. 2000

EN

Official Journal of the European Communities

L 33/21

COMMISSION DECISION

of 14 January 2000

detailing the distribution between antigen banks of antigen reserves established within the frame-
work of the Community action concerning reserves of foot-and-mouth disease vaccines and
amending Commission Decisions 93/590/EC and 97/348/EC

(notified under document number C(2000) 1)

(Text with EEA relevance)

(2000/112/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European
Community,

Having regard to Council Decision 91/666/EEC of 11
December 1991 establishing Community reserves of foot-and-
mouth disease vaccines (1), as
last amended by Council
Decision 1999/762/EC (2), and in particular Articles 7 thereof,

Whereas:

(1)

(2)

(3)

(4)

(5)

in accordance with Article 7 of Council Decision 91/
666/EEC the Commission shall adopt detailed arrange-
ments in particular with regard to the distribution of
antigen reserves between antigen banks;

antigens within

Article 3 of Commission Decision 93/590/EC of 5
November 1993, for the purchase of foot-and-mouth
the
framework
disease
Community action concerning reserves of
foot-and-
mouth disease vaccines (3) as last amended by Decision
95/471/EC (4), makes provisions for the antigen to be
stored at three specified locations;

the

of

Commission Decision 97/348/EC of 23 May 1997 for
the purchase by the Community of
foot-and-mouth
disease antigens and for the formulation, production,
bottling and distribution of vaccines against foot-and-
the distribution of newly
mouth disease (5), details
purchased antigen to designated antigen banks;

by Decision 2000/111/EC (6)
the Commission desig-
nated Merial SAS, Pirbright, United Kingdom as a third
antigen bank and made provisions for the transfer of
antigen from a bank no longer designated;

as regards the quantities and types of antigen stored at
designated antigen banks account must be taken of the
new situation and for the sake of clarity these quantities

(6)

(7)

and types of antigen should be listed for each designated
antigen bank according to the new situation;

the provisions of Article 3 of Decision 93/590/EC and
of Article 5 of Decision 97/348/EC are no longer
adapted to the new situation and should be repealed;

the measures provided for in this Decision are in accord-
ance with the opinion of
the Standing Veterinry
Committee,

HAS ADOPTED THIS DECISION:

Article 1

The quantities and types of antigen stored within the frame-
work of Community reserves of
foot-and-mouth disease
antigen shall be distributed between designated antigen banks
in accordance with the provisions in the Annex.

Article 2

1.

2.

Article 3 of Decision 93/590/EC is repealed.

Article 5 of Decision 97/348/EC is repealed.

Article 3

This Decision shall apply from 1 February 2000.

This Decision is addressed to the Member States.

Article 4

Done at Brussels, 14 January 2000.

For the Commission

David BYRNE

Member of the Commission

(1) OJ L 368, 31.12.1991, p. 21.
(2) OJ L 301, 24.11.1999, p. 6.
(3) OJ L 280, 13.11.1993, p. 33.
(4) OJ L 269, 11.11.1995, p. 29.
(5) OJ L 148, 6.6.1997, p. 27.
(6) See page 19 of this Official Journal.

L 33/22

EN

Official Journal of the European Communities

8. 2. 2000

ANNEX

EUROPEAN
ANTIGEN BANK

Designated antigen banks

EUROPEAN
ANTIGEN BANK

IZP
Brescia

LNPB
Lyon

Merial S.A.S.
Pirbright

Antigen
type/subtype

Quantity (1)
(× 1 000 000)

Quantity (1)
(× 1 000 000)

Quantity (1)
(× 1 000 000)

Quantity (1)
(× 1 000 000)
total per antigen

O1 — Manissa

O1 — BFS

A24 — Cruzeiro

A22 — Iraq

C1 — Noville

ASIA1 — Shamir

Quantity (1)
(× 1 000 000)
total per site

2,5

—

—

2,5

2,5

2,5

2,5

2,5

2,5

3,9

—

—

—

2,5

2,5

—

2,5

2,5

5,0

5,0

5,0

6,4

5,0

5,0

10,0

11,4

10,0

31,4

(1) Quantity in vaccine equivalent antigen doses.